OMIC - Singular Genomics Systems PEG Multiple

Demand for pharmaceuticals remains stable, but sanctions are weighing on raw material supplies. The PEG ratio trend reflects the current valuation of Singular Genomics Systems (OMIC), where the parameter is 0.00. Growth is supported by partnerships with laboratories to implement sequencing systems, although capital-intensive R&D and marketing requirements are temporarily constraining the company's free cash flow.

Singular Genomics - OMIC PEG Multiple (period 07/04/2022 - 03/01/2025)

Singular Genomics Systems (OMIC) - metric breakdowns and financial figures

- market value and analyst target forecast:

Price Rate Chart Singular Genomics Systems, Inc.|OMIC - Consensus Target

- market capitalization statistics:

Market Capitalization Singular Genomics Systems Inc|OMIC - Total Company Value

- balance sheet equity data:

Net Assets per Single Share Singular Genomics|OMIC - Book Capitalization|Market Capitalization to Book Value Ratio singulargenomics.com|OMIC - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Singular Genomics Systems|OMIC - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital singulargenomics.com|OMIC - Company Aggregate Debts|Debt to Net Assets Singular Genomics Systems Inc|OMIC - Company Long-Term Debts|Short-Term Debt Singular Genomics|Immediate Liquidity Ratio singulargenomics.com

- financial results and valuation multiples details:

OMIC - Company Net Income|Expected Net Profit Singular Genomics Systems|OMIC - Price to Earnings Ratio|Projected Price to Earnings Singular Genomics Corp|OMIC - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Singular Genomics Systems Inc|OMIC - Operating profit EBITDA|Net earnings per share for the last 12 months Singular Genomics|OMIC - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months singulargenomics.com|OMIC - Net earnings per share growth this year|Expected earnings per share trend next year Singular Genomics Systems

General company analysis:Singular Genomics Systems

Finished products of singulargenomics.com

Investors are assessing the resilience of Singular Genomics (OMIC) by comparing the P/E multiple to earnings growth rates, which allows for the identification of asset undervaluation when the value falls below one. An analysis of the weighted PEG ratio helps determine whether management can protect the value of the sequencing platform amid strategic adaptation, transforming operational risks into fundamental capitalization potential.

Competing companies